Marine Drugs (Aug 2023)

Anti-Hyperlipidemic Effect of Fucoidan Fractions Prepared from Iceland Brown Algae <i>Ascophyllum nodosum</i> in an Hyperlipidemic Mice Model

  • Yunhai He,
  • Yutong Li,
  • Peili Shen,
  • Shangkun Li,
  • Linsong Zhang,
  • Qiukuan Wang,
  • Dandan Ren,
  • Shu Liu,
  • Demeng Zhang,
  • Hui Zhou

DOI
https://doi.org/10.3390/md21090468
Journal volume & issue
Vol. 21, no. 9
p. 468

Abstract

Read online

Ascophyllum nodosum, a brown algae abundantly found along the North Atlantic coast, is recognized for its high polysaccharide content. In this study, we investigated the anti-hyperlipidemic effect of fucoidans derived from A. nodosum, aiming to provide information for their potential application in anti-hyperlipidemic therapies and to explore comprehensive utilization of this Iceland brown seaweed. The crude fucoidan prepared from A. nodosum was separated using a diethylethanolamine column, resulting in two fucoidan fractions, AFC-1 and AFC-2. Both fractions were predominantly composed of fucose and xylose. AFC-1 exhibited a higher sulfate content of 27.8% compared to AFC-2 with 17.0%. AFC-2 was primarily sulfated at the hydroxy group of C2, whereas AFC-1 was sulfated at both the hydroxy groups of C2 and C4. To evaluate the anti-hyperlipidemic effect, a hyperlipidemia mouse model was established by feeding mice a high-fat diet. The effects of AFC-1, AFC-2, and the crude extract were investigated, with the drug atorvastatin used as a positive comparison. Among the different fucoidan fractions and doses, the high dose of AFC-2 administration demonstrated the most significant anti-hyperlipidemic effect across various aspects, including physiological parameters, blood glucose levels, lipid profile, histological analysis, and the activities of oxidative stress-related enzymes and lipoprotein-metabolism-related enzymes (p p A. nodosum as a promising therapeutic solution for hypolipidemia.

Keywords